Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma

Robert Frank Cornell, Parameswaran Hari, Mei Jie Zhang, Xiabao Zhong, Jonathan Thompson, Timothy S. Fenske, Mary M. Horowitz, Richard Komorowski, Jeanne Palmer, Marcelo C. Pasquini, J. Douglas Rizzo, Wael Saber, Mathew Thomas, William R. Drobyski

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Engraftment syndrome (ES) is an increasingly observed and occasionally fatal complication after autologous peripheral blood stem cell transplantation (PBSCT). In this study, we demonstrate that the incidence of ES is significantly increased in patients undergoing autologous PBSCT for multiple myeloma in comparison to patients with non-Hodgkin lymphoma or Hodgkin lymphoma. Multivariate analysis revealed that age > 60 (hazard ratio [HR], 1.71; 95% confidence interval [CI], 1.12 to 2.62; P= .013) and transplantation for multiple myeloma (HR, 2.80; 95% CI, 1.60 to 4.90; P= .0003) were associated with an increased risk of this complication. When stratified for myeloma patients only, age > 60 (HR, 1.80; 95% CI, 1.13 to 2.87; P= .013) and prior treatment with both lenalidomide and bortezomib (HR, 1.83; 95% CI, 1.11 to 3.04; P= .0001) were associated with an increased incidence of ES. Conversely, lack of exposure to cyclophosphamide from either chemomobilization or as a component of the pretransplantation therapeutic regimen increased the risk of this complication (HR, 3.05; 95% CI, 1.91 to 4.87; P <.0001). These studies demonstrate that the pretransplantation exposure of multiple myeloma patients to novel immunomodulatory agents and cyclophosphamide significantly affects the subsequent risk of developing ES.

Original languageEnglish (US)
Pages (from-to)1368-1373
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume19
Issue number9
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Peripheral Blood Stem Cell Transplantation
Multiple Myeloma
Cyclophosphamide
Confidence Intervals
Incidence
Hodgkin Disease
Non-Hodgkin's Lymphoma
Multivariate Analysis
Transplantation
Therapeutics

Keywords

  • Autologous graft-versus-host
  • Autologous peripheral stem cell
  • Disease
  • Engraftment syndrome
  • Multiple myeloma
  • Transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. / Cornell, Robert Frank; Hari, Parameswaran; Zhang, Mei Jie; Zhong, Xiabao; Thompson, Jonathan; Fenske, Timothy S.; Horowitz, Mary M.; Komorowski, Richard; Palmer, Jeanne; Pasquini, Marcelo C.; Rizzo, J. Douglas; Saber, Wael; Thomas, Mathew; Drobyski, William R.

In: Biology of Blood and Marrow Transplantation, Vol. 19, No. 9, 01.01.2013, p. 1368-1373.

Research output: Contribution to journalArticle

Cornell, RF, Hari, P, Zhang, MJ, Zhong, X, Thompson, J, Fenske, TS, Horowitz, MM, Komorowski, R, Palmer, J, Pasquini, MC, Rizzo, JD, Saber, W, Thomas, M & Drobyski, WR 2013, 'Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma', Biology of Blood and Marrow Transplantation, vol. 19, no. 9, pp. 1368-1373. https://doi.org/10.1016/j.bbmt.2013.06.017
Cornell, Robert Frank ; Hari, Parameswaran ; Zhang, Mei Jie ; Zhong, Xiabao ; Thompson, Jonathan ; Fenske, Timothy S. ; Horowitz, Mary M. ; Komorowski, Richard ; Palmer, Jeanne ; Pasquini, Marcelo C. ; Rizzo, J. Douglas ; Saber, Wael ; Thomas, Mathew ; Drobyski, William R. / Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. In: Biology of Blood and Marrow Transplantation. 2013 ; Vol. 19, No. 9. pp. 1368-1373.
@article{cf96bd10be7a4f8eaa08caeb8f8eb9ec,
title = "Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma",
abstract = "Engraftment syndrome (ES) is an increasingly observed and occasionally fatal complication after autologous peripheral blood stem cell transplantation (PBSCT). In this study, we demonstrate that the incidence of ES is significantly increased in patients undergoing autologous PBSCT for multiple myeloma in comparison to patients with non-Hodgkin lymphoma or Hodgkin lymphoma. Multivariate analysis revealed that age > 60 (hazard ratio [HR], 1.71; 95{\%} confidence interval [CI], 1.12 to 2.62; P= .013) and transplantation for multiple myeloma (HR, 2.80; 95{\%} CI, 1.60 to 4.90; P= .0003) were associated with an increased risk of this complication. When stratified for myeloma patients only, age > 60 (HR, 1.80; 95{\%} CI, 1.13 to 2.87; P= .013) and prior treatment with both lenalidomide and bortezomib (HR, 1.83; 95{\%} CI, 1.11 to 3.04; P= .0001) were associated with an increased incidence of ES. Conversely, lack of exposure to cyclophosphamide from either chemomobilization or as a component of the pretransplantation therapeutic regimen increased the risk of this complication (HR, 3.05; 95{\%} CI, 1.91 to 4.87; P <.0001). These studies demonstrate that the pretransplantation exposure of multiple myeloma patients to novel immunomodulatory agents and cyclophosphamide significantly affects the subsequent risk of developing ES.",
keywords = "Autologous graft-versus-host, Autologous peripheral stem cell, Disease, Engraftment syndrome, Multiple myeloma, Transplantation",
author = "Cornell, {Robert Frank} and Parameswaran Hari and Zhang, {Mei Jie} and Xiabao Zhong and Jonathan Thompson and Fenske, {Timothy S.} and Horowitz, {Mary M.} and Richard Komorowski and Jeanne Palmer and Pasquini, {Marcelo C.} and Rizzo, {J. Douglas} and Wael Saber and Mathew Thomas and Drobyski, {William R.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2013.06.017",
language = "English (US)",
volume = "19",
pages = "1368--1373",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma

AU - Cornell, Robert Frank

AU - Hari, Parameswaran

AU - Zhang, Mei Jie

AU - Zhong, Xiabao

AU - Thompson, Jonathan

AU - Fenske, Timothy S.

AU - Horowitz, Mary M.

AU - Komorowski, Richard

AU - Palmer, Jeanne

AU - Pasquini, Marcelo C.

AU - Rizzo, J. Douglas

AU - Saber, Wael

AU - Thomas, Mathew

AU - Drobyski, William R.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Engraftment syndrome (ES) is an increasingly observed and occasionally fatal complication after autologous peripheral blood stem cell transplantation (PBSCT). In this study, we demonstrate that the incidence of ES is significantly increased in patients undergoing autologous PBSCT for multiple myeloma in comparison to patients with non-Hodgkin lymphoma or Hodgkin lymphoma. Multivariate analysis revealed that age > 60 (hazard ratio [HR], 1.71; 95% confidence interval [CI], 1.12 to 2.62; P= .013) and transplantation for multiple myeloma (HR, 2.80; 95% CI, 1.60 to 4.90; P= .0003) were associated with an increased risk of this complication. When stratified for myeloma patients only, age > 60 (HR, 1.80; 95% CI, 1.13 to 2.87; P= .013) and prior treatment with both lenalidomide and bortezomib (HR, 1.83; 95% CI, 1.11 to 3.04; P= .0001) were associated with an increased incidence of ES. Conversely, lack of exposure to cyclophosphamide from either chemomobilization or as a component of the pretransplantation therapeutic regimen increased the risk of this complication (HR, 3.05; 95% CI, 1.91 to 4.87; P <.0001). These studies demonstrate that the pretransplantation exposure of multiple myeloma patients to novel immunomodulatory agents and cyclophosphamide significantly affects the subsequent risk of developing ES.

AB - Engraftment syndrome (ES) is an increasingly observed and occasionally fatal complication after autologous peripheral blood stem cell transplantation (PBSCT). In this study, we demonstrate that the incidence of ES is significantly increased in patients undergoing autologous PBSCT for multiple myeloma in comparison to patients with non-Hodgkin lymphoma or Hodgkin lymphoma. Multivariate analysis revealed that age > 60 (hazard ratio [HR], 1.71; 95% confidence interval [CI], 1.12 to 2.62; P= .013) and transplantation for multiple myeloma (HR, 2.80; 95% CI, 1.60 to 4.90; P= .0003) were associated with an increased risk of this complication. When stratified for myeloma patients only, age > 60 (HR, 1.80; 95% CI, 1.13 to 2.87; P= .013) and prior treatment with both lenalidomide and bortezomib (HR, 1.83; 95% CI, 1.11 to 3.04; P= .0001) were associated with an increased incidence of ES. Conversely, lack of exposure to cyclophosphamide from either chemomobilization or as a component of the pretransplantation therapeutic regimen increased the risk of this complication (HR, 3.05; 95% CI, 1.91 to 4.87; P <.0001). These studies demonstrate that the pretransplantation exposure of multiple myeloma patients to novel immunomodulatory agents and cyclophosphamide significantly affects the subsequent risk of developing ES.

KW - Autologous graft-versus-host

KW - Autologous peripheral stem cell

KW - Disease

KW - Engraftment syndrome

KW - Multiple myeloma

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=84882809747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882809747&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2013.06.017

DO - 10.1016/j.bbmt.2013.06.017

M3 - Article

C2 - 23806770

AN - SCOPUS:84882809747

VL - 19

SP - 1368

EP - 1373

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 9

ER -